ZEUCF yields 52631.58% · JNJ yields 2.13%● Live data
📍 ZEUCF pulled ahead of the other in Year 1
Combined, ZEUCF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ZEUCF + JNJ for your $10,000?
ZeU Technologies Inc. engages in the block-chain technology development business. The company offers distributed ledger technology (DLT)-based secure email system, which authenticates the sender and the recipient, encrypts the data, and stores it on the distributed storage service; random numbers generation technology to create actual random numbers; cross-chain transactions technology; transactional decentralized communication protocol infrastructure, a system that removes the smart contract layer; distributed data real-time backup and recovery, a system for realizing real-time data backup and recovery based on DLT; converting database applications into DLT applications; biocrypt digital wallet technology, a biometric digital wallet for the cold storage of cryptocurrencies; augmenting database applications technology with DLT; and symmetric asynchronous generative encryption technology for security of data. It also provides Mula platform, a modular platform that anonymizes and protects a user's online information; MulaMail, an enterprise solution; safe custody of private data using blockchain technology; and permission-based multi-level encryption scheme document for decentralized storage. In addition, the company offers virtual identity and user management infrastructure; ZeU Gaming platform; and ZeUPay for custodial and legacy banking support for the Mula platform, as well as operates mula.education, which allows users to practice the encryption methods used in the Mula platform. The company was formerly known as ZeU Crypto Networks Inc. and changed its name to ZeU Technologies Inc. in October 15, 2020. ZeU Technologies Inc. was incorporated in 2018 and is headquartered in Montreal, Canada.
Full ZEUCF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.